Regenerative medicine could potentially cure diseases and may replace palliative treatments for chronic diseases. Stem cells in particular have been studied for their regenerative properties: their potential to repair or replace damaged or diseased human cells or tissues to restore normal function. Studies of stem cell therapies targeting cardiovascular indications such as heart failure (HF), myocardial infarction (MI), cardiomyopathy (CM), and left ventricular dysfunction (LVD) aim to demonstrate that stem cells injected into the circulation or directly into the injured heart tissue improve cardiac function and/or induce the formation of new capillaries.
This report provides an assessment of the pipeline, clinical, and commercial landscape of stem cell therapies in CVMD. Overall, GlobalData expects new stem cell therapy approvals to drive CVMD market growth from 2018–2025.

Scope

GlobalData’s Hot Topic: Stem Cell Therapies in CVMD combines KOL and Payer insights along with data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the slide deck include:

• Overview of CVMD and Stem Cells—epidemiology and regulatory oversight

• Pipeline Assessment—regional breakdown, promising late-stage products, early-stage pipeline by molecule type

• Clinical Trials Assessment—trial breakdown by phase, leading industry and non-industry sponsors

• Market Access—considerations for reimbursement, pricing, and unmet needs

• Market Outlook—competitive assessment and key market events (2018–2025)

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global CVMD stem cell therapy market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global CVMD stem cell therapy market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Key Players

Mesoblast
U.S. Stemcell
Celixir
Capricor
Stemedica
Healios
Athersys
SanBio

Table of Contents

Table of Contents (PowerPoint Deck)

1 Introduction

1.1 Related Reports

1.2 Upcoming Related Reports

2 Executive Summary

2.1 Key Findings

2.2 CVMD Stem Cell Therapy Competitive Landscape Insights

3 Overview – Stem Cells, CVMD, Epidemiology

3.1 Regenerative Medicine

3.2 Stem Cells and Cardiovascular Disease

3.3 Stem Cell Therapies

3.4 Overview of Heart Disease and Epidemiology

3.5 Overview of Other CV Indications and Epidemiology

3.6 Overview of Metabolic Disorders and Epidemiology

4 Regulatory Oversight of Stem Cell Therapies

4.1 Regulatory Agencies in the US and EU

4.2 The FDA and Stem Cell Therapy

4.3 Oversight of Stem Cell Therapy in Japan and China

4.4 Marketed Heart Failure Therapy in Japan

5 Pipeline Assessment, Profiled Stem Cell Therapies

5.1 Pipeline Stem Cell Therapies Targeting CVMD

5.2 Stem Cell Therapies for Heart Failure

5.3 HF Pipeline: Mesoblast’s Revascor

5.4 HF Pipeline: U.S. Stemcell’s MyoCell

5.5 HF Pipeline: Celixir’s Heartcel

5.6 HF Pipeline: Capricor’s CAP-1002

5.7 HF Pipeline: Stemedica’s Stemedyne-MSC

5.8 Stroke Pipeline: Healios’/Athersys’ Multistem

5.9 Stroke Pipeline: SanBio’s SB623

6 Clinical Trials and Key Developers

6.1 Overview of Clinical Trials

6.2 CVMD Stem Cell Therapy Development

6.3 Clinical Trial Mapping

6.4 Key Players

7 Market Access: Reimbursement, Pricing, Unmet Need

7.1 Market Access

7.2 Stem Cell Therapy Reimbursement

7.3 Unmet Need within CVD

7.4 CVD Stem Cell Therapy Reimbursement and Pricing

7.5 Reimbursement for HF Stem Cell Pipeline Therapies

7.6 Reimbursement for Stroke Stem Cell Pipeline Therapies

7.7 MD (Diabetes) Stem Cell Therapy Reimbursement

8 Market Outlook

8.1 Market Outlook for Mesoblast’s Revascor

8.2 Market Outlook for U.S. StemCell’s MyoCell

8.3 Market Outlook for Celixir’s Heartcel

8.4 Market Outlook for Capricor’s CAP-1002

8.5 Market Outlook for Stemedica’s Stemedyne-MSC

8.6 Market Outlook for Healios’/Athersys’ Multistem

8.7 Market Outlook for SanBio’s SB623

8.8 Anticipated Key Events for Stem Cell Therapies in CVD

9 Appendix

9.1 Sources

9.2 Methodology

9.3 Primary Research

9.4 About the Authors

9.5 About GlobalData

9.6 Contact Us

9.7 Disclaimer

$7,995

Can be used by individual purchaser only

$23,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022